Latest News and Press Releases

G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024

G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent DMC

G1 Therapeutics provides Corporate and Clinical Update at the 42md Annual J.P. Morgan healthcare conference.

G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

January 2024 Inducement Grants

G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent

RESEARCH TRIANGLE PARK, N.C., Dec. 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...

New data at the 2023 SABCS explore the long-term impact of trilaciclib on survival outcomes in patients with metastatic TNBC